	US 11,723,978 B2
	Ganciclovir compositions and related methods
Sreerama Murthy Mallipeddi, Hickory, NC (US); Jonathan E. Sterling, Morganton, NC (US); and Phanesh B. Koneru, Ashburn, VA (US)
Assigned to Exela Pharma Sciences, LLC, Lenoir, NC (US)
Filed by Exela Pharma Sciences, LLC, Lenoir, NC (US)
Filed on Mar. 10, 2020, as Appl. No. 16/814,871.
Application 16/814,871 is a continuation of application No. 15/345,970, filed on Nov. 8, 2016, abandoned.
Application 15/345,970 is a continuation of application No. 14/475,206, filed on Sep. 2, 2014, granted, now 9,486,530, issued on Nov. 8, 2016.
Claims priority of provisional application 61/872,625, filed on Aug. 30, 2013.
Prior Publication US 2020/0316075 A1, Oct. 8, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/26 (2006.01); A61K 31/522 (2006.01); A61K 47/02 (2006.01); A61K 9/08 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01)

CPC A61K 47/26 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/522 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01)]

18 Claims

1. A stable, injectable, ready to administer, sterile, particulate-matter-free, aqueous parenteral dosage form for parenteral administration to a subject, consisting essentially of:

ganciclovir at a concentration of from 1 mg/ml to 3 mg/ml;

a tonicity agent; and

optionally a pH adjuster,

wherein the composition has a pH of from 5 to 9.